Your browser doesn't support javascript.
loading
Beneficial effects resulting from oral administration of Escherichia coli Nissle 1917 on a chronic colitis model.
Souza, E L S; Campos, C L V; Reis, D C; Cassali, G D; Generoso, S V; Cardoso, V N; Azevedo, V; Medeiros, J D; Fernandes, G R; Nicoli, J R; Martins, F S.
  • Souza ELS; Department of Microbiology, Federal University of Minas Gerais, Belo Horizonte, CEP 31270-901, MG, Brazil.
  • Campos CLV; Department of Microbiology, Federal University of Minas Gerais, Belo Horizonte, CEP 31270-901, MG, Brazil.
  • Reis DC; Department of General Pathology, Federal University of Minas Gerais, Presidente Antônio Carlos 6627, Belo Horizonte, CEP 31270-901, MG, Brazil.
  • Cassali GD; Department of General Pathology, Federal University of Minas Gerais, Presidente Antônio Carlos 6627, Belo Horizonte, CEP 31270-901, MG, Brazil.
  • Generoso SV; Department of Nutrition, Federal University of Minas Gerais, Alfredo Balena 190, Belo Horizonte, CEP 30130-100, MG, Brazil.
  • Cardoso VN; Department of Clinical and Toxicological Analysis, Federal University of Minas Gerais, Av. Antônio Carlos 6627, Pampulha, Belo Horizonte, CEP 31270-901, MG, Brazil.
  • Azevedo V; Department of Genetic, Ecology and Evolution, Federal University of Minas Gerais, Belo Horizonte, CEP 31330-500, MG, Brazil.
  • Medeiros JD; René Rachou Institute - Fiocruz Minas, Augusto de Lima 1715, Belo Horizonte, MG, Brazil.
  • Fernandes GR; René Rachou Institute - Fiocruz Minas, Augusto de Lima 1715, Belo Horizonte, MG, Brazil.
  • Nicoli JR; Department of Microbiology, Federal University of Minas Gerais, Belo Horizonte, CEP 31270-901, MG, Brazil.
  • Martins FS; Department of Microbiology, Federal University of Minas Gerais, Belo Horizonte, CEP 31270-901, MG, Brazil.
Benef Microbes ; 11(8): 779-790, 2020 Dec 02.
Article en En | MEDLINE | ID: mdl-33191778
ABSTRACT
Inflammatory bowel diseases (IBD) are chronic processes involving a deregulated immune response against intestinal microbiota in genetically susceptible individuals. Ulcerative colitis (UC) is an IBD restricted to colonic mucosa and its chronicity is a predisposing factor for colorectal cancer (CRC). Probiotics have been investigated as an adjuvant treatment for UC, and Escherichia coli Nissle 1917 (EcN) was the focus of our investigation. The aim of this study was to investigate the preventive effect of the EcN probiotic in an experimental model of chronic colitis in germ-free (GF) and conventional (CV) mice. CV female mice were used for clinical, immunological and permeability experiments. GF mice were used for a faecal microbiota transplantation assay. To induce colitis, three cycles of 3.0% dextran sulphate sodium (DSS) were administered to the animals. For probiotic treatment, the mice received a daily intragastric gavage of 9.0 log10 cfu of EcN, beginning 10 days before colitis induction and continuing until the end of the experiment. EcN presented beneficial effects when administered preventively. Daily Disease Activity Index (DAI) evolution demonstrated significant difference in remission periods after the first two DSS cycles and during the third one. Reduction in bacterial translocation after probiotic treatment indicated protection of the intestinal barrier. Associated with mucosal preservation, restoration of secretory immunoglobulin A levels and reduction of interleukin (IL)-5, IL-13, tumour necrosis factor and interferon-γ levels were observed in EcN treatment. Finally, when microbiota modification was verified, 16S rRNA-based compositional analysis showed variation of intestinal microbiota between the control and colitis groups. After faecal transplantation using GF mice, it was observed that EcN treatment in CV mice might result in modulated intestinal microbiota. This was observed indirectly in the reduced daily DAI, when colitis was compared with treated group. In conclusion, EcN presented beneficial effects in this model, suggesting its usefulness for treating UC.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Probióticos / Escherichia coli / Trasplante de Microbiota Fecal / Mucosa Intestinal Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Probióticos / Escherichia coli / Trasplante de Microbiota Fecal / Mucosa Intestinal Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article